Evidence map›Paper›PMID 42249510›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026

Long-term prognostic value of

Wenyan Gao, Jingwen Peng, Xue Chen, Yi Wang, Shunji Zhi, Lei Wu, Gang Wan, Zhuzhong Cheng, Qifeng Wang, Wei Zhang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenyan Gao *Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jingwen Peng *Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Xue Chen *Cancer Center, Sichuan Taikang Hospital, Tianfu New Area, #881 Xiang He First Street, Chengdu, Sichuan Province, China.
Yi WangDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Shunji ZhiDepartment of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lei WuDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Gang WanDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Zhuzhong ChengDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Qifeng WangDepartment of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. littlecancer@163.com.
Wei ZhangDepartment of Nuclear Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. zwmary84512@163.com.

Funding

the Science and Technology Department of Sichuan Province 2023YFS0488 and 2023YFQ0055
6 · The paper itself

Abstract

backgroundAccurate prognostication in locally advanced oesophageal squamous cell carcinoma (LA-ESCC) remains a significant clinical challenge. This prospective study aimed to compare the predictive value of fluorine-18 fluorodeoxyglucose (

methodsBetween June 2018 and July 2019, 31 patients with LA-ESCC were prospectively enrolled and underwent both

resultsIn

conclusions

Indexed as

DideoxynucleosidesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAgedFemaleHumansMaleMiddle AgedPrognosisProspective StudiesRadiopharmaceuticalsalovudineDideoxynucleosidesFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG18F-FLTOesophageal squamous cell carcinomaPositron emission tomographyPrognosis

Identifiers

PMID42249510
PMCPMC13459923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.